<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788434</url>
  </required_header>
  <id_info>
    <org_study_id>CONSORTIUM (VE303-002)</org_study_id>
    <nct_id>NCT03788434</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection</brief_title>
  <acronym>CONSORTIUM</acronym>
  <official_title>CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedanta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedanta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of VE303 for participants with primary C.
      difficile infection (pCDI) at high risk for recurrence or subjects with recurrent C.
      difficile infections (rCDI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CONSORTIUM is a randomized, double-blind phase 2 study to evaluate safety, tolerability,
      PK/PD, and efficacy of VE303 in prevention of subsequent CDI-associated diarrhea compared
      with placebo following completion of at least 1 successful course of standard-of-care (SOC)
      antibiotics. VE303 or placebo capsules will be taken orally for 14 days after completion of a
      course of standard of care antibiotics. The proportion of subjects experiencing a confirmed
      CDI recurrence, within 8 weeks after the first dose of study treatment, will be compared
      across the study arms to understand the effectiveness of VE303 in preventing rCDI.

      The study will enroll approximately 146 to 300 subjects with a prior history of CDI diarrhea
      or first occurrence of CDI diarrhea with a higher risk for recurrence. Subjects must also
      have a positive C. difficile stool sample and have responded to standard of care (SOC)
      antibiotic treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This Phase 2 study will help determine how safe and effective the study drug, VE303, is at preventing subsequent Clostridium difficile Infection (CDI)-associated diarrhea compared with placebo, following completion of at least 1 successful course of standard-of-care (SOC) antibiotics for subjects with primary C. difficile infection (pCDI) at high risk for recurrence or subjects with recurrent CDI.
Patients in the study will be randomized into 3 arms in a 1:1:1 ratio of high dose VE303, low dose VE303, and placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>To reduce potential bias and increase study data integrity, study participants, care providers, site investigators, and study outcomes assessors will all be masked to study treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Selection of Phase 3 dose for VE303</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary objective is to determine the recommended VE303 Phase 3 dose regimen based on safety and efficacy, as indicated by the C difficile infection (CDI) recurrence rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize VE303 colonization</measure>
    <time_frame>24 weeks</time_frame>
    <description>Secondary objective is to characterize VE303 colonization in the fecal microbiome after 14 days of treatment with VE303.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Changes in the Fecal Microbiome</measure>
    <time_frame>24 weeks</time_frame>
    <description>Secondary objective is to characterize changes in the fecal microbiome after 14 days of treatment with VE303.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CDI recurrence week 8</measure>
    <time_frame>8 weeks after first study dose</time_frame>
    <description>Proportion of subjects with CDI recurrence before or at Week 8 (i.e., 8 weeks after the first dose of study treatment).</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 4</measure>
    <time_frame>4 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 4 (i.e., 4 weeks after the first dose of study treatment)</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 12</measure>
    <time_frame>12 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 12 (i.e., 12 weeks after the first dose of study treatment)</description>
  </other_outcome>
  <other_outcome>
    <measure>CDI recurrence week 24</measure>
    <time_frame>24 weeks after first study dose</time_frame>
    <description>Proportion of subjects without CDI recurrence before or at Week 24 (i.e., 24 weeks after the first dose of study treatment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiota diversity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in fecal taxonomic composition after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <other_outcome>
    <measure>Taxonomic Composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in fecal taxonomic composition after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolomic profile</measure>
    <time_frame>24 weeks</time_frame>
    <description>Changes in the fecal metabolomic profile, including short chain fatty acids and bile acids after 14 days of blinded treatment with VE303.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Clostridium Difficile Infection Recurrence</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile</condition>
  <condition>CDI</condition>
  <arm_group>
    <arm_group_label>VE303 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VE303 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VE303</intervention_name>
    <description>VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under GMP conditions.</description>
    <arm_group_label>VE303 High Dose</arm_group_label>
    <arm_group_label>VE303 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules contain micro-crystalline cellulose. They are visually identical to VE303 capsules. They will be taken by mouth for 14 days. Placebo capsules will not contain any VE303 Drug Product.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Partial Inclusion Criteria:

          1. Able and willing to provide written informed consent

          2. Subjects with a qualifying CDI episode who have a prior history of CDI diarrhea or
             first occurrence of CDI diarrhea with a higher risk for recurrence (≥ 65 years of age)

          3. CDI symptoms must have started within 30 days (inclusive) prior to the day of
             randomization

          4. The diarrhea is considered unlikely to have another etiology.

          5. Complete an Investigator's choice SOC antibiotic regimen of a minimum of 10 days and
             up to 21 days of total duration

          6. Have a positive C. difficile stool

          7. Recovered from any complications of severe or fulminant CDI and clinically stable by
             the time of randomization.

        Partial Exclusion Criteria:

          1. History of diarrhea (defined as 3 or more loose stools per day lasting for at least 4
             weeks) that is not related to C. difficile infection within the 3 months prior to
             randomization.

          2. Known or suspected toxic megacolon and/or known small bowel ileus at the time of
             randomization.

          3. Contraindication to oral/enteral therapy (e.g., severe reflux, severe nausea/vomiting,
             or ileus).

          4. Prior administration of genetically modified investigational live
             bacterial/fungal/bacteriophage/viral isolates for CDI-associated diarrhea

          5. History of administration of fecally-derived investigational live biotherapeutic
             products, or fecally-derived live bacterial isolates for CDI-associated diarrhea
             including fecal microbiota transplantation (FMT) within the last 6 months.

          6. Use of drugs that alter gut motility

          7. History of acute leukemia or hematopoietic stem cell transplantation or
             myelosuppressive chemotherapy within 2 months prior to randomization.

          8. Subjects with compromised immune system

          9. Major gastrointestinal surgery (e.g., significant bowel resection or diversion) within
             3 months prior to randomization or any history of total colectomy or bariatric surgery
             that disrupts the gastrointestinal lumen.

         10. History of confirmed celiac disease, inflammatory bowel disease, short gut,
             gastrointestinal tract fistulas, or ischemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lorraine Hughes</last_name>
    <phone>857-706-1427</phone>
    <email>Consortium02-ctinquiries@vedantabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelsey Brown, BA</last_name>
    <phone>857-706-1427</phone>
    <email>Consortium02-ctinquiries@vedantabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Clinical, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Blums</last_name>
      <phone>480-213-8765</phone>
      <email>craigblums@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Daisy Vasquez, MS, SC</last_name>
      <phone>480-213-8765</phone>
      <email>daisy@phxclinical.onmicrosoft.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brock Merritt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Clinical Studies Unit</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen Vy</last_name>
      <phone>480-342-1328</phone>
      <email>nguyen.vy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Orenstein, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Meyers, RN, CRC</last_name>
      <phone>870-936-8406</phone>
      <email>dana.hammett@neabc.com</email>
    </contact>
    <investigator>
      <last_name>Homer Brooks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance Research Institute</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omo Imaku</last_name>
      <phone>951-283-3402</phone>
      <email>oimaku@allianceri.org</email>
    </contact>
    <investigator>
      <last_name>Saleem Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Centers, Inc.</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonni Molgaard</last_name>
      <phone>530-247-7049</phone>
      <email>jmolgaard@paradigm-research.com</email>
    </contact>
    <investigator>
      <last_name>Thiruvoipati NandaKumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-200-7436</phone>
      <email>sabinehazan@aim.com</email>
    </contact>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Osborn</last_name>
      <phone>727-584-6368</phone>
      <phone_ext>201</phone_ext>
      <email>TraceyO@InnovativeResearchFL.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Trevino, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastro Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Brewington</last_name>
      <phone>727-336-7682</phone>
      <email>sbrewington@gastrofl.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gollwitzer</last_name>
      <phone>352-294-5481</phone>
      <email>JGollwitzer@dental.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NAPA Research</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magda Hernandez</last_name>
      <phone>954-901-1599</phone>
      <email>mhernandez@napatrials.com</email>
    </contact>
    <investigator>
      <last_name>Naval Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guardian Angel Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Porro</last_name>
      <phone>813-512-7479</phone>
      <email>lporrod@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angel Rosario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharma Research Associates</name>
      <address>
        <city>Westchester</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belkys Rodriguez</last_name>
      <phone>786-508-7884</phone>
      <email>pharmaresearchBVR@gmail.com</email>
    </contact>
    <investigator>
      <last_name>John Cosby, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Graham</last_name>
      <phone>404-712-2962</phone>
      <email>allen.w.graham@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Collen Kraft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Snake River Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Morrison</last_name>
      <phone>208-535-8406</phone>
      <email>jmorrison@snakerr.com</email>
    </contact>
    <investigator>
      <last_name>Martha Buitrago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisphere Medical Research Center</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carissa Covert</last_name>
      <phone>812-471-4110</phone>
      <email>ccovert@medisphereresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Dela Llana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CroNOLA, LLC</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Benoit</last_name>
      <phone>504-930-4860</phone>
      <email>hbenoit@cronola.com</email>
    </contact>
    <investigator>
      <last_name>Nathanial Winstead, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Raymond</last_name>
      <phone>504-842-4005</phone>
      <email>laraymond@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Julia Garcia-Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research</name>
      <address>
        <city>Zachary</city>
        <state>Louisiana</state>
        <zip>70791</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Dours</last_name>
      <phone>225-654-9901</phone>
      <email>tammy@southernclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ernest Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System Research Insitute</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Gray</last_name>
      <phone>443-481-5868</phone>
      <email>Kgray7@aahs.org</email>
    </contact>
    <investigator>
      <last_name>James Welker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capitol Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Klepeis</last_name>
    </contact>
    <investigator>
      <last_name>Ajay Bakhshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Parker</last_name>
      <phone>671-636-1577</phone>
      <email>jparker@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Yoav Golan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Torres Soto</last_name>
      <phone>617-724-8625</phone>
      <email>mtorressoto@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Hohmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Barrett</last_name>
      <phone>617-667-8266</phone>
      <email>cbarret5@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Alonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Foley</last_name>
      <phone>774-442-4098</phone>
      <email>Anne.foley@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Jean Marie Houghton, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covenant HealthCare</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wasmiller</last_name>
      <phone>989-583-6232</phone>
      <email>SWasmiller@chs-mi.com</email>
    </contact>
    <investigator>
      <last_name>Menelito Lilagan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Dept of Medicine, IDIM Division</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsea Seep</last_name>
      <phone>612-625-8090</phone>
      <email>keepx005@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Partricia Kammer</last_name>
      <phone>507-538-1827</phone>
      <email>kammer.patricia@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Darrell Pardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Jarman</last_name>
      <phone>314-362-1176</phone>
      <email>sjarman@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Grant Bochicchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adirondack Medical Research Center</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Kilbfliesh</last_name>
      <phone>518-798-9401</phone>
      <email>D.kalbfliesh@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhavna Sharma</last_name>
      <phone>646-501-8818</phone>
      <email>Bhavna.Sharma@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Jordan Axelrad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Macon</last_name>
      <phone>704-675-7144</phone>
      <email>lmacon@crgastonia.com</email>
    </contact>
    <investigator>
      <last_name>William Watkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Hill</last_name>
      <phone>336-659-8414</phone>
      <email>chill@southeasternresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Barry Sigal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research Inc</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abbas Zaidi</last_name>
      <phone>419-843-8815</phone>
      <email>abbas.zaidi@ohmiallergy.com</email>
    </contact>
    <investigator>
      <last_name>Syed Rehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TruCare Internal Medicine and Infectious Diseases</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Woodel</last_name>
      <phone>814-371-2348</phone>
      <email>cawoodel@trucareinternalmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Tusdae Stainbrook, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frontier Clinical Research, LLC</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Black</last_name>
      <phone>724-550-4099</phone>
      <email>jblack@frontierclinical.com</email>
    </contact>
    <investigator>
      <last_name>Frederick Ruthardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Care Access Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Cooley</last_name>
      <phone>401-773-7855</phone>
      <email>melissa@careaccessresearch.com</email>
    </contact>
    <investigator>
      <last_name>Sudhir Bansal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Rock Hill</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Bongermino</last_name>
      <phone>803-746-4542</phone>
      <email>cbongermino@cresrh.com</email>
    </contact>
    <investigator>
      <last_name>Amir Rezk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naheed Mehkri</last_name>
      <phone>832-641-8718</phone>
      <email>naheedm2002@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Haider Afzal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research-Be Well MD</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Jacobsen</last_name>
      <phone>512-506-8287</phone>
      <email>cjacobsen@acr-research.com</email>
    </contact>
    <investigator>
      <last_name>Mark Carlson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Centers for Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligita Cooper</last_name>
      <phone>817-348-0042</phone>
      <email>lcooper@tcida.net</email>
    </contact>
    <investigator>
      <last_name>Cheryl McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Anastasiades</last_name>
      <phone>832-915-5458</phone>
      <email>jenna@centexstudies.com</email>
    </contact>
    <investigator>
      <last_name>Joe Pouzar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fmc Science, Llc</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cain</last_name>
      <phone>512-556-4130</phone>
      <email>sbent@fmcscience.com</email>
    </contact>
    <investigator>
      <last_name>James Cain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinrx Research Joseph INC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vandana Agarwal</last_name>
      <phone>214-680-9321</phone>
      <email>vandana@clinrxresearch.com</email>
    </contact>
    <investigator>
      <last_name>John Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Associates of Central Virginia Infectious Disease</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh McConaghy</last_name>
      <phone>434-947-3900</phone>
      <phone_ext>2135</phone_ext>
      <email>mcconaghyl@intravene.net</email>
    </contact>
    <investigator>
      <last_name>Robert Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Infectious Disease Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Forrest Ursprung</last_name>
      <phone>206-682-3444</phone>
      <email>forrestu@seattleidc.com</email>
    </contact>
    <investigator>
      <last_name>Warren Dinges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research-Spokane Gastroenterology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Sullivan</last_name>
      <phone>509-309-6227</phone>
      <email>asullivan@acr-research.com</email>
    </contact>
    <investigator>
      <last_name>Harold Preiksaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CARe Clinic</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <zip>T4N6V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauna Whalen</last_name>
      <phone>403-343-8972</phone>
      <phone_ext>105</phone_ext>
      <email>Shauna.whalen@careclinicrd.ca</email>
    </contact>
    <investigator>
      <last_name>Morne Odendaal, MB, ChB, LMCC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Margeson</last_name>
      <phone>506-857-5821</phone>
      <email>alyssa.margeson@horizonnb.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Smyth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Gilchrist</last_name>
      <phone>905 522-1155</phone>
      <email>jgilchri@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Marek Smieja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viable Clinical Research</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Morley</last_name>
      <phone>(519) 859-9589</phone>
      <email>amorley@viableclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Debra Butt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Québec-Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Chabot</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>47778</phone_ext>
      <email>isabelle.chabot@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Marie-Louise Vachon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Tapps</last_name>
      <phone>819-697-3333</phone>
      <phone_ext>63547</phone_ext>
      <email>danielle_tapps@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Andre Poirier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium Difficile Infection Recurrence</keyword>
  <keyword>Clostridium Difficile Infection</keyword>
  <keyword>Clostridium Difficile</keyword>
  <keyword>VE303</keyword>
  <keyword>Consortium</keyword>
  <keyword>Vedanta</keyword>
  <keyword>CDI</keyword>
  <keyword>C. Diff</keyword>
  <keyword>CDiff</keyword>
  <keyword>Clostridiodes Difficile Infection</keyword>
  <keyword>Clostridiodes Difficile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

